LAB282
  • Home
  • About
    • LAB282
    • Funded Projects
    • IP & Commercialisation
    • LAB282 Support
  • Applications
    • Applying to LAB282
    • Application FAQs
  • Team
    • Partners
    • Steering Committee
    • Industry Experts
    • OUI Support
  • Case Studies
    • Myelofibrosis
    • Myocarditis
    • Next-Generation Antibiotics
  • News
  • Contact
Select Page

APPLYING TO LAB282

PROCESS, KEY MILESTONES AND

APPLICATION FORM

LAB282 welcomes ad hoc applications, as well as applications in response to specific calls that it may issue. Interested academics should first talk to both the LAB282 Expert in Residence (EIR) and a member of the Licensing and Ventures Group in Oxford University Innovation (OUI), the  university’s technology transfer office, see contacts page.

Applications may be for up to up to £500K in total, with funding split between the PI’s lab and the industrial partner Evotec, with the split depending on the project’s scientific requirements.

The application form is available via the link below, and should be submitted upon recommendation by the EIR and following prior review and sign off by OUI and your Departmental Administrator. Please note that applications will only be accepted if they are accompanied by a fully costed proposal, which has been pre-approved by Research Services according to the standard grant application procedure (X5 costing).

Award applications will be reviewed quarterly by the LAB282 Joint Steering Committee, and will require an in-person pitch.

The LAB282 Joint Steering Committee (JSC) meets on a quarterly basis, typically in March, June, September and December.

Joint Steering Committee dates, and application deadlines, are:

JSC date Application deadline
14th December 2021 12th November 2021

Lab282 is currently not accepting new applications, for further info and updates please contact Christine Whyte or Thomas Hanke.

DOWNLOAD APPLICATION FORM

Lab282 Partners

LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2022. All rights reserved